公开(公告)号：US20220259140A1

公开(公告)日：2022-08-18

申请号：US17738373

申请日：2022-05-06

申请人： Shandong Danhong Pharmaceutical Co., Ltd.

发明人： Yang ZHANG ,  Wentao WU ,  Zhixiang LI

IPC分类号： C07C219/26

摘要： The present invention relates to a crystal form and an amorphous form of dezocine analogue hydrochloride, and in particularly, to a crystal form of a compound represented by formula (I) and an amorphous form of a compound represented by formula (II). An X-ray powder diffraction spectrum of the crystal form comprises characteristic peaks at 20 values of 13.1°±0.2°, 16.8±0.2°, and 18.5±0.2°, and an X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.

公开(公告)号：US11021445B2

公开(公告)日：2021-06-01

申请号：US16700978

申请日：2019-12-02

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Yang Zhang ,  Wentao Wu ,  Zhixiang Li ,  Mingxing Teng ,  Guangwen Yang ,  Jie Li ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D217/26 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

摘要： The present invention relates to a compound shown in formula (II) or a pharmaceutically acceptable salt thereof and an application of the same in preparing a drug for treating a disease related to angiotensin II receptor type 2 (AT2R).(II)

公开(公告)号：US10822365B1

公开(公告)日：2020-11-03

申请号：US16916108

申请日：2020-06-30

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Chengde Wu ,  Qinghua Mao ,  Yi Li ,  Tao Yu ,  Shuhui Chen

IPC分类号： C07H15/14 ,  A61P3/10

摘要： A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190218189A1

公开(公告)日：2019-07-18

申请号：US16242753

申请日：2019-01-08

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Weihua SHI ,  Feng XU ,  Zheng WANG ,  Weidong LI ,  Linghui WU ,  Hongwei LI ,  Minggao ZENG ,  Kunmin LAI ,  Zhigan JIANG ,  Haiying HE

IPC分类号： C07D235/06 ,  C07D487/10 ,  A61K31/4184 ,  C07D209/96 ,  A61P31/12 ,  B01D9/00 ,  C07B41/06 ,  C07B43/04

CPC分类号： C07D235/06 ,  A61K31/4184 ,  A61P31/12 ,  B01D9/0004 ,  B01D9/0054 ,  C07B41/06 ,  C07B43/04 ,  C07B2200/13 ,  C07D209/96 ,  C07D487/10

摘要： Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

公开(公告)号：US11339119B2

公开(公告)日：2022-05-24

申请号：US16611926

申请日：2018-06-29

申请人： Shandong Danhong Pharmaceutical Co., Ltd.

发明人： Yang Zhang ,  Wentao Wu ,  Zhixiang Li

IPC分类号： C07C219/26

摘要： The present invention relates to a crystal form and an amorphous form of dezocine analogue hydrochloride, and in particularly, to a crystal form of a compound represented by formula (I) and an amorphous form of a compound represented by formula (II). An X-ray powder diffraction spectrum of the crystal form comprises characteristic peaks at 2θ values of 13.1°±0.2°, 16.8±0.2°, and 18.5±0.2°, and an X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.

公开(公告)号：US20220024880A1

公开(公告)日：2022-01-27

申请号：US17311431

申请日：2019-12-20

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Zhi LUO ,  Xiaolin LI ,  Yaxun YANG ,  Lele YANG ,  Peng LI ,  Haiying HE ,  Jian LI ,  Shuhui CHEN

IPC分类号： C07D249/08

摘要： Disclosed are a process route of a compound of a compound of formula (IV), a crystal form and a preparation method therefor. Also disclosed is an application of the crystal form in preparation of drugs for treating diseases associated with SSAO.

公开(公告)号：US20210198220A1

公开(公告)日：2021-07-01

申请号：US17191161

申请日：2021-03-03

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Zhi LUO ,  Xiaolin LI ,  Yaxun YANG ,  Lele YANG ,  Peng LI ,  Haiying HE ,  Jian LI ,  Shuhui CHEN

IPC分类号： C07D271/10 ,  A61P1/16 ,  C07D231/12 ,  C07D235/18 ,  C07D239/08 ,  C07D239/26 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D261/20 ,  C07D263/57 ,  C07D271/06 ,  C07D277/24 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04

摘要： The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190010114A1

公开(公告)日：2019-01-10

申请号：US16066852

申请日：2017-01-04

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Yang ZHANG ,  Wentao WU ,  Zhixiang LI ,  Guangwen YANG ,  Yongbo FANG ,  Tao ZHANG ,  Wei GU ,  Shuhui CHEN ,  Fei WANG ,  Jian LI

IPC分类号： C07C215/64 ,  C07D313/20

CPC分类号： C07C215/64 ,  C07C217/74 ,  C07C219/26 ,  C07C255/59 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2603/80 ,  C07D313/20

摘要： Disclosed in the present disclosure is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.

公开(公告)号：US11897830B2

公开(公告)日：2024-02-13

申请号：US17738373

申请日：2022-05-06

申请人： Shandong Danhong Pharmaceutical Co., Ltd.

发明人： Yang Zhang ,  Wentao Wu ,  Zhixiang Li

IPC分类号： C07C219/26

CPC分类号： C07C219/26 ,  C07B2200/13 ,  C07C2603/80

摘要： An amorphous form of dezocine analogue hydrochloride is represented by formula (II). An X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.

公开(公告)号：US20220324897A1

公开(公告)日：2022-10-13

申请号：US17596900

申请日：2020-07-03

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Qinghua MAO ,  Tao YU ,  Yi LI ,  Chengde WU ,  Ting YAO

IPC分类号： C07H7/04 ,  C07H1/00 ,  C07H1/06

摘要： Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.